IL245936A0 - Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers - Google Patents

Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers

Info

Publication number
IL245936A0
IL245936A0 IL245936A IL24593616A IL245936A0 IL 245936 A0 IL245936 A0 IL 245936A0 IL 245936 A IL245936 A IL 245936A IL 24593616 A IL24593616 A IL 24593616A IL 245936 A0 IL245936 A0 IL 245936A0
Authority
IL
Israel
Prior art keywords
predictors
biomarkers
treatment
methods
blood cancer
Prior art date
Application number
IL245936A
Other languages
English (en)
Hebrew (he)
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of IL245936A0 publication Critical patent/IL245936A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL245936A 2013-12-06 2016-05-31 Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers IL245936A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
IL245936A0 true IL245936A0 (en) 2016-07-31

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245936A IL245936A0 (en) 2013-12-06 2016-05-31 Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers

Country Status (12)

Country Link
US (1) US20160312292A1 (enExample)
EP (1) EP3077547A4 (enExample)
JP (1) JP2017503481A (enExample)
KR (1) KR20160090390A (enExample)
AU (1) AU2014360316A1 (enExample)
BR (1) BR112016012792A2 (enExample)
CA (1) CA2932266A1 (enExample)
EA (1) EA201691143A1 (enExample)
IL (1) IL245936A0 (enExample)
MX (1) MX2016007179A (enExample)
PH (1) PH12016501023A1 (enExample)
WO (1) WO2015085160A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
WO2016060557A1 (en) * 2014-10-17 2016-04-21 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
EP3347717A4 (en) 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US20200270703A1 (en) * 2017-09-29 2020-08-27 Kyushu University, National University Corporation Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients
MX2022004688A (es) * 2019-10-21 2022-05-10 Celgene Corp Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona.
WO2024258819A1 (en) * 2023-06-15 2024-12-19 The Broad Institute, Inc. Neoplastic cytotoxicity induced by glycosylation
FR3158744A1 (fr) * 2024-01-30 2025-08-01 Universite Grenoble Alpes Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
EP2544687A1 (en) * 2010-03-12 2013-01-16 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
MX353482B (es) * 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.

Also Published As

Publication number Publication date
WO2015085160A3 (en) 2015-07-30
WO2015085160A2 (en) 2015-06-11
BR112016012792A2 (pt) 2017-08-08
US20160312292A1 (en) 2016-10-27
AU2014360316A1 (en) 2016-06-16
EP3077547A2 (en) 2016-10-12
EP3077547A4 (en) 2017-11-08
KR20160090390A (ko) 2016-07-29
PH12016501023A1 (en) 2016-07-04
MX2016007179A (es) 2016-09-08
EA201691143A1 (ru) 2016-11-30
CA2932266A1 (en) 2015-06-11
JP2017503481A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
IL260400B (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
IL245936A0 (en) Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers
IL243408A0 (en) Diagnosis and therapy of cancer involving cancer stem cells
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
IL280039B (en) Compositions and methods related to diagnosis of prostate cancer
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
IL276300A (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
IL234989B (en) Compounds and compositions thereof for treating cancer
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
HUE050828T2 (hu) DLL3-kötõ reagenseket tartalmazó rákterápiás és rákdiagnosztikai célmolekulák
HUE046292T2 (hu) Melanóma kezelése és diagnosztizálása
EP2968191A4 (en) METHOD FOR THE TREATMENT OF BUBBLE CANCER
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
IL239007B (en) Eribulin for use in the treatment of breast cancer
IL236664A0 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
IL225262A0 (en) Methods and compositions for treating lung cancer
PT3626270T (pt) Tratamento de doenças cardiovasculares
HUE050485T2 (hu) Tauopathia kezelési módszerei
EP3084000A4 (en) Method of diagnosis and treatment
IL234993B (en) Methods and compositions for treating ewing's sarcoma family of tumors
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL236197A0 (en) In vitro method for the diagnosis and surveillance of cancer
IL243570B (en) Compositions and kits for the treatment of atopic dermatitis
PT3052525T (pt) Anticorpos anti-epcam e métodos de utilização
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment